Hacettepe University, Department of Pediatrics, Section of Pediatric Hematology, Ankara, Turkey.
Leuk Res. 2010 Aug;34(8):1012-7. doi: 10.1016/j.leukres.2010.02.002. Epub 2010 Mar 1.
Homozygous W374X mutation was identified in unrelated 13 patients (6M/7F) from consanguineous families, 62% of which had history of deceased sibling. Haplotype analysis provided evidence for the probable existence of a founder effect. Age at disease onset ranged from 1 day to 5.5 months (median 2 months). Hepatic dysfunction was observed in 69%, ascite 62%, hypertriglyceridemia 77%, each hyperferritinemia and hypofibrinogenemia 85%, CNS involvement 46% of patients while birth weights were in normal range. Those with very high ferritin (>20,000ng/ml) had extremely low fibrinogen levels. Two-thirds of patients receiving HLH protocol died within 20 days of therapy.
在 13 名无关的近亲家庭患者(6 男/7 女)中发现了纯合 W374X 突变,其中 62%有死亡同胞的病史。单体型分析为可能存在的 founder 效应提供了证据。发病年龄从 1 天至 5.5 个月不等(中位数为 2 个月)。69%的患者出现肝功能异常,62%出现腹水,77%出现高三酰甘油血症,85%的患者出现每个高铁蛋白血症和低纤维蛋白原血症,46%的患者出现中枢神经系统受累,而出生体重均在正常范围内。那些铁蛋白非常高(>20,000ng/ml)的患者纤维蛋白原水平极低。接受 HLH 方案治疗的患者中有三分之二在 20 天内死亡。